-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Arcus Biosciences, Lowers Price Target to $45

Benzinga·11/05/2026 13:47:00
Listen to the news
Wedbush analyst Robert Driscoll maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and lowers the price target from $49 to $45.